A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment

Exclusion Criteria

• •Have used insulin therapy (outside of pregnancy) anytime in the past 2 years, except for short term treatment of acute conditions
• •Have been treated with rosiglitazone, pramlintide, glucagon-like peptide-1 (GLP-1) receptor agonist within 3 months prior to screening
• •Are using or have used any of the following lipid-lowering medications: niacin preparations as a lipid-lowering medication and/or bile acid sequestrants within 90 days prior to screening
• •Local OAM restrictions: have any restrictions for cardiac, renal, and hepatic diseases in the local product regulations
• •Are taking, or have taken within 3 months before screening, prescription or over-the-counter medications to promote weight loss
• •Have had any episodes of severe hypoglycemia, diabetic ketoacidosis, or hyperosmolar state/coma within 6 months prior to screening
• •Have had 1 or more episodes of ketoacidosis or hyperosmolar state/coma in the past 6 months
• •Have cardiac disease with functional status that is New York Heart Association Class III or IV
• •Have a history of renal transplantation, or are currently receiving renal dialysis or have serum creatinine ≥2.0 milligram per deciliter (mg/dL) (177 micromole per liter \[μmol/L\]). Participants taking metformin should not exceed the creatinine level specified in the local label
• •Have obvious clinical signs or symptoms of liver disease (excluding non-alcoholic fatty liver disease \[NAFLD\]), acute or any chronic hepatitis, non alcoholic steatohepatitis (NASH), or elevated liver enzyme measurements
• •Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the measurement of HbA1c
• •Have active or untreated cancer, have been in remission from clinically significant cancer(other than basal cell or squamous cell skin cancer) for less than 5 years, or are at increased risk for developing cancer or a recurrence of cancer in the opinion of the investigator
• •Have known hypersensitivity or allergy to any of LY2605541 and insulin glargine or their excipients
• •Have pre proliferative and proliferative retinopathy, maculopathy requiring treatment or not clinically stable in the last 6 months, or participants with active changes in subjective eye symptoms as determined by the investigator if an eye exam has not been performed in the last 6 months
• •Are receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy (excluding topical, intranasal, intraocular, and inhaled preparations) or have received such therapy within the 8 weeks immediately preceding screening
• •Have fasting triglycerides greater than 400 mg/dL (4.5 mmol/L) at screening as determined by the central laboratory
• •Have an irregular sleep/wake cycle (for example, participants who sleep during the day and work during the night) in the investigator's opinion